knowledge -WSS

knowledge

author：focus 2025-10-01 17:34:40 - browse：69746

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Custom gene therapy hints at new path for rare disease treatments

focus

leisure time

WSS

WHO calls for emergency meeting on new China virus, as cases spread

Listen: Wegovy in the brain & pivotal Alzheimer's data

Dog Aging Project founders on what lies ahead after losing funding

FDA sets aggressive timeline for overhauling inspection procedures

In early work, researchers turn to CRISPR to treat Alzheimer's

Medicare has a new plan to address drug shortages

knowledge

knowledge

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

How to save PrEP access — and even expand it

Mass General, Mayo Clinic look to monetize custom

Supreme Court strikes down use of affirmative action

FDA sets aggressive timeline for overhauling inspection procedures

Hollywood unions extend contract negotiations for actors

Biden tests positive for Covid

Wildfire smoke exposes gaps in outdoor worker protections

Custom gene therapy hints at new path for rare disease treatments

hotspot

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

FDA approves RSV monoclonal antibody for infants, toddlers

What causes osteoarthritis? Researchers study link to brain protein

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Microsoft launches AI tool for clinical documentation through Epic

focus

leisure time

hotspot

hotspot